Qiagen N.v. · NYSE:QGEN

Qiagen — Q3 2021 Earnings Presentation

29 slides from Qiagen's earnings presentation, Nov 4, 2021

  1. Slide 1: Q3 2021 results

    DRAFT – 202211102 – 1300 HILDEN Q3 2021 results November 4, 2021 Sample to Insight

  2. Slide 2: Forward looking and intended use statements

    Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be, deemed to be forward looking statements within the meaning of Section 27A of the U.S.

  3. Slide 3: Q3 2021: Summary

    Q3 2021: Summary 1 2 High-performing Strengthening portfolio Strong cash flow Upgraded 2021 outlook base business Reflects strong Q3 results Five pillars of growth Dynamic 198% rise in free +17% CER growth in performing well and setting cash flow while investing in Net sales: ≥ +15% CER non-COVID pr

  4. Slide 4: Q3 2021: Ongoing solid trends in non-COVID product group sales growth

    Q3 2021: Ongoing solid trends in non-COVID product group sales growth Net sales exceeded outlook +10% CER vs. Q3 2020 +17% CER in non-COVID product groups Adj. EPS exceeded outlook $0.58 CER vs. $0.52-0.53 CER FY 2021 outlook upgraded Healthy cash flow Strengthening foundation for future growth ≥ +1

  5. Slide 5: Q3 2021: All product groups delivering growth in non-COVID areas

    Q3 2021: All product groups delivering growth in non-COVID areas Sales by product group Q3 2021 sales (In $ millions at actual rates) ■ Sample technologies +10% CER • Mid-single digit CER growth in non-COVID group sales vs. decline in COVID-19 product group sales $571 $567 $567 • Strong QIAprep&amp

  6. Slide 6: Q3 2021: Growth in all regions as non-COVID sales gain momentum

    Q3 2021: Growth in all regions as non-COVID sales gain momentum Americas • Dynamic QuantiFERON sales growth of >50% CER • +19% CER growth in the U.S. Europe / Middle East / Africa • Ongoing demand for COVID testing solutions • UK, Italy, Belgium and Switzerland all grew at double-digit CER rates Ame

  7. Slide 7: Q3 2021: Five pillars update – investing to drive sustainable post-pandemic expansion

    Q3 2021: Five pillars update – investing to drive sustainable post-pandemic expansion Sample QIAcuity QuantiFERON NeuMoDx QIAstat-Dx technologies digital PCR • PAXgene Saliva • QIAreach-QFT TB • New COVID-19 • U.S. government • Respiratory 4-plex Collector launched launched as modern wastewater test

  8. Slide 8: Q3 2021: New Diagnostic solutions set for launch to address key market opportunities

    Q3 2021: New Diagnostic solutions set for launch to address key market opportunities QIAstat-Dx Respiratory 4-plex panel CE-IVD QIAreach QuantiFERON-TB Increased use of multiplex panels for respiratory illness diagnosis Unique capabilities for high-disease burden, low-resource areas % of all respira

  9. Slide 9: Q3 2021: Investing in business expansion while returning value to shareholders

    Q3 2021: Investing in business expansion while returning value to shareholders Adjusted EPS Adj. operating Operating Cash Targeted investments into five pillars of growth income Flow Manufacturing scale-up and test menu expansion for QIAstat-Dx and NeuMoDx (In $ per share) (In $ millions) (In $ mill

  10. Slide 10: Outlook: Full-year 2021 outlook updated to reflect stronger than expected Q3 results

    Outlook: Full-year 2021 outlook updated to reflect stronger than expected Q3 results FY 2021 outlook FY 2021 outlook Q4 2021 outlook Updated Previous (July 2021) Net sales ~ -9% CER ≥ +15% CER ≥ +12% CER Anticipated currency impact Up to -1 p.p ~ + 2 p.p. ~ + 2-3 p.p. Adjusted EPS ≥ $0.60 CER ≥ $2.4

  11. Slide 11: Appendix

    Appendix Sample to Insight

  12. Slide 12: Q4 and FY 2021: Outlook and assumptions

    Q4 and FY 2021: Outlook and assumptions (As of November 3, 2021) Q4 2021 outlook FY 2021 outlook ~ -9% CER ≥ +15% CER Net sales (Prior year: $571.2 m) (Prior year: $1,870.3 m) Anticipated currency impact(1) Up to -1 p.p. ~ +2 p.p. > $0.60 CER ≥ $2.48 CER Adjusted EPS(2) (Prior year: $0.68) (Prior ye

  13. Slide 13: Q3: Consolidated Statements of Income (unaudited)

    Q3: Consolidated Statements of Income (unaudited) Three months ended Three months ended (In $ thousands, except share data) September 30, 2021 September 30, 2020 Net sales 534,745 483,763 Cost of sales: Cost of sales 181,214 147,297 Acquisition-related intangible amortization 16,314 15,692 Total cos

  14. Slide 14: 9M: Consolidated Statements of Income (unaudited)

    9M: Consolidated Statements of Income (unaudited) Nine months ended Nine months ended (In $ thousands, except share data) September 30, 2021 September 30, 2020 Net sales 1,669,259 1,299,112 Cost of sales: Cost of sales 540,576 394,084 Acquisition-related intangible amortization 51,687 45,746 Total c

  15. Slide 15: 2021: Quarterly sales by product group

    2021: Quarterly sales by product group Q1 2021 Q2 2021 Q3 2021 Q4 2021 9M 2021 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 227 47% 42% 203 1% -3% 202 -5% -6% 632 11% 8% Diagnostic solutio

  16. Slide 16: 2020: Quarterly sales by product group

    2020: Quarterly sales by product group Q1 2020 Q2 2020 Q3 2020 Q4 2020 FY 2020 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 154 22% 24% 200 46% 49% 214 57% 56% 236 59% 55% 804 47% 47% Diag

  17. Slide 17: 2021: Sales by non-COVID and COVID-19 product groups

    2021: Sales by non-COVID and COVID-19 product groups Q1 2021 Q2 2021 Q3 2021 Q4 2021 9M 2021 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Non-COVID product groups 364 20% 16% 408 57% 52% 376 18% 17% 1,148 30%

  18. Slide 18: 2020: Sales by non-COVID and COVID-19 product groups

    2020: Sales by non-COVID and COVID-19 product groups Q1 2020 Q2 2020 Q3 2020 Q4 2020 FY 2020 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Non-COVID product groups 303 -5% -4% 259 -25% -23% 320 -8% -8% 371 0%

  19. Slide 19: 2021: Quarterly sales by product type, customer class and region

    2021: Quarterly sales by product type, customer class and region (In $ millions at actual rates / change in actual, CER rates) Q1 2021 Q2 2021 Q3 2021 Q4 2021 9M 2021 Product type Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Consumables and related revenues 498 53% 48%

  20. Slide 20: 2020: Quarterly sales by product type, customer class and region

    2020: Quarterly sales by product type, customer class and region (In $ millions at actual rates / change in actual, CER rates) Q1 2020 Q2 2020 Q3 2020 Q4 2020 FY 2020 Product type Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Consumables and related revenues 326 4% 6% 37

  21. Slide 21: Q3 and 9M 2021: Reconciliation adjusted results (unaudited)

    Q3 and 9M 2021: Reconciliation adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pretax Income Tax Net Diluted Third quarter 2021 sales profit income income tax rate income EPS Reported results 534.7 337.2 131.9 151.5 (18.3) 12% 133.1 0.57 Adjustments Business integration,

  22. Slide 22: Q3 and 9M 2021: Footnotes for reconciliation adjusted results (unaudited)

    Q3 and 9M 2021: Footnotes for reconciliation adjusted results (unaudited) (a) Results for 2021 include integration-related activities for the NeuMoDx acquisition in September 2020. Results for 2020 include expenses associated with the public takeover offer for QIAGEN. A restructuring program was ini

  23. Slide 23: 2021: Quarterly income statement summary

    2021: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2021 Q2 2021 Q3 2021 Q4 2021 9M 2021 Net sales 567.2 567.3 534.7 1,669.3 Net sales (CER) 549.5 547.7 530.8 1,628.0 Gross profit 370.6 369.2 337.2 1,077.0 Gross profit margin 65.3% 65.1% 63.1% 6

  24. Slide 24: 2020: Quarterly and full-year income statement summary

    2020: Quarterly and full-year income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2020 Q2 2020 Q3 2020 Q4 2020 FY 2020 Net sales 372.1 443.3 483.8 571.2 1,870.3 Gross profit 243.5 295.0 320.8 373.4 1,232.7 Gross profit margin 65.5% 66.5% 66.3% 65.4% 65.9% Adjus

  25. Slide 25: Consolidated Balance Sheets

    Consolidated Balance Sheets September 30, December 31, September 30, December 31, (In $ thousands, except par value) 2021 2020 (In $ thousands, except par value) 2021 2020 Assets (unaudited) Liabilities and Equity (unaudited) Cash and cash equivalents 617,541 597,984 Current portion of long-term deb

  26. Slide 26: Consolidated Statements of Cash Flows (unaudited)

    Consolidated Statements of Cash Flows (unaudited) Nine months ended Nine months ended September 30, September 30, September 30, September 30, (In $ thousands) 2021 2020 (In $ thousands) 2021 2020 Cash flows from operating activities: Cash flows from financing activities: Net income 383,413 146,503 R

  27. Slide 27: Q3 and 9M 2021: Currency impact

    Q3 and 9M 2021: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q3 2021 U.S. dollar 270.7 270.7 51% 0.0 Euro 110.6 109.8 21% -0.8 British pound 24.0 22.5 4% -1.5 Japanese yen 16.1 16.7 3% 0.6 Other currencies 113.3 111.1

  28. Slide 28: Employees as of September 30, 2021

    Employees as of September 30, 2021 Europe / Asia Pacific / Total Total Americas Middle East / Africa Japan / ROW Q3 2021 Q3 2020 Change Production 445 1,220 154 1,819 1,329 37% R&D 221 734 48 1,003 893 12% Sales 580 870 808 2,258 2,173 4% Marketing 81 184 85 350 319 10% Administration 80 388 158 626

  29. Slide 29: Your contacts

    Your contacts John Gilardi Vice President Corporate Communications and IR Calendar Phone: +49 2103 29 11711 Q4 2021 results February 2022 Mobile: +49 152 018 11711 E-mail: john.gilardi@qiagen.com Q1 2022 results April 2022 Annual General Meeting June 2022 Phoebe Loh Senior Director Share information

Qiagen — Q3 2021 Earnings Presentation on 6ix